GIPathfinder

GIPathfinder

Rigidizing overtube enhances GI endoscope control

Overview

Pathfinder develops a rigidizing overtube to improve endoscope control during gastrointestinal (GI) procedures. It addresses endoscope looping by allowing the overtube to instantly switch from flexible to rigid, stabilizing the endoscope and making navigation easier in complex cases and altered anatomy. The product works by being placed over the endoscope during a procedure; in flexible mode it slides with the scope, and when rigidity is needed, it becomes stiff to prevent looping, guiding the scope more precisely. Pathfinder differentiates itself from competitors by offering a quick toggle between flexible and rigid states, focusing specifically on GI procedures such as luminal therapeutics and ERCP, and targeting improved procedural efficiency and success rates in hospitals and clinics. The company aims to improve procedural outcomes, shorten procedure times, and enhance patient care by providing a reliable solution to endoscope looping that supports clinicians in difficult cases.

About GIPathfinder

Simplify's Rating
Why GIPathfinder is rated
C-
Rated C on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Healthcare

Company Size

51-200

Company Stage

Series D

Total Funding

$97M

Headquarters

Burlingame, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance in August 2019 enables adoption in leading U.S. hospitals.
  • Pathfinder CR for Upper GI Bleed available now, expanding therapeutic applications.
  • Initial 29-patient study in 2020 demonstrated utility in loop management procedures.

What critics are saying

  • Neptune Medical's Pathfinder overtube, FDA-cleared K230801 in 2023, erodes market share.
  • Neptune lawsuit forces rebranding, incurring $2–5M costs and stalling sales.
  • Olympus acquires Neptune, undercuts pricing by 40% in 18–24 months.

What makes GIPathfinder unique

  • Pathfinder overtube toggles from flexible to rigid using Dynamic Rigidization™ technology.
  • 85 cm overtube accommodates pediatric colonoscopes and stiffens 15 times under vacuum.
  • Single-use disposable design eliminates abdominal pressure and position changes.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$97M

Above

Industry Average

Funded Over

1 Rounds

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Above Average

Industry standards

$77M
$70M
Twilio
$80M
Handshake
$97M
GIPathfinder
$100M
Affirm

Benefits

Health Insurance

Paid Vacation

Paid Holidays

Flexible Work Hours

Remote Work Options

401(k) Retirement Plan

401(k) Company Match

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Adoption Assistance

Childcare Support

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

26%
The Robot Report
Oct 4th, 2024
Robotics Investments Near $1B In August

Listen to this articleSwiss-Mile raised $22M in August 2024 for its wheeled quadruped. Fifty producers of robots and robotics enabling technologies received funding in August 2024, pulling in a total of approximately $1 billion. This figure is on par with the $1.2 billion average The Robot Report has tracked each of the previous 12 months. Investment targeted to robotics companies for the first eight months of 2024 equals about $10.86 billion. You can follow The Robot Report‘s investment section here. The largest investments in August were secured by developers of autonomous driving technologies

Business Wire
Aug 17th, 2024
Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Neptune Medical announces $97 million in Series D financing, along with the spinout of its Jupiter Endovascular subsidiary.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for GIPathfinder right now.

Find jobs on Simplify and start your career today

We update GIPathfinder's jobs every few hours, so check again soon! Browse all jobs →